NCT01371227View on ClinicalTrials.gov

A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Multiple Myeloma
Interventions
DRUG

JNS002

30 mg/m2 by intravenous infusion at a rate of = 1 mg/minute on Day 4 of each 21-day cycle.

Trial Locations (2)

Unknown

Nagoya

Okayama

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY